Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Apr 13;5(4):e007244.
doi: 10.1136/bmjopen-2014-007244.

Effect of glucomannan supplementation on body weight in overweight and obese children: protocol of a randomised controlled trial

Bartłomiej Mateusz Zalewski  1 , Hania Szajewska  1
Affiliations
Randomized Controlled Trial

Effect of glucomannan supplementation on body weight in overweight and obese children: protocol of a randomised controlled trial

Bartłomiej Mateusz Zalewski et al. BMJ Open. .

Abstract

Introduction: Glucomannan (GNN), a water-soluble dietary fibre derived from the plant Amorphophallus konjac, is marketed for weight reduction. The exact mechanisms by which GNN might exert its actions are unclear. However, it has been shown that GNN slows gastric emptying by forming a viscous gel of large volume, which increases the feeling of satiety. Current evidence on the effectiveness of GNN for weight reduction is sparse, and well-designed trials performed in children are needed to assess the efficacy of this modality. We aim to systematically evaluate the efficacy of GNN consumption for the management of children who are overweight or obese.

Methods and analysis: Children aged 6-17 years who are overweight or obese (based on the WHO growth criteria) will be randomly assigned to receive GNN or placebo (maltodextrin) (both at a dose of 3 g/day) for 3 months and will be followed-up for 3 months. Before the intervention, all children will receive dietetic advice, and they will be encouraged to engage in physical activity. The primary outcome measure will be the body mass index-for-age z-score difference between the groups at the end of the intervention.

Ethics and dissemination: The study was approved by the Bioethics Committee of the Medical University of Warsaw. The findings of this trial will be submitted to a peer-reviewed journal (paediatric, nutrition or gastroenterology). Abstracts will be submitted to relevant national and international conferences.

Trial registration number: NCT02280772.

Keywords: Obesity; children; glucomannan.

PubMed Disclaimer

References

    1. Ng M, Fleming T, Robinson M et al. . Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014;384:766–81. 10.1016/S0140-6736(14)60460-8[Published Online First 29 May 2014]. - DOI - PMC - PubMed
    1. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011;128(Suppl 5):S213–56. 10.1542/peds.2009-2107C [Published Online First 14 Nov 2011]. - DOI - PMC - PubMed
    1. Kalavainen M, Korppi M, Nuutinen O. Long-term efficacy of group-based treatment for childhood obesity compared with routinely given individual counselling. Int J Obes (Lond) 2011;35:530–3. 10.1038/ijo.2011.1 [Published Online First 1 Feb 2011]. - DOI - PubMed
    1. Keithley J, Swanson B. Glucomannan and obesity: a critical review. Altern Ther Health MedAlternative Therapies in Health and Medicine 2005;11:30–344. - PubMed
    1. EFSA Panel on Dietetic Products NaAN. Scientific Opinion on the substantiation of health claims related to konjac mannan (glucomannan) and reduction of body weight (ID 854, 1556, 3725), reduction of post-prandial glycaemic responses (ID 1559), maintenance of normal blood glucose concentrations (ID 835, 3724), maintenance of normal (fasting) blood concentrations of triglycerides (ID 3217), maintenance of normal blood cholesterol concentrations (ID 3100, 3217), maintenance of normal bowel function (ID 834, 1557, 3901) and decreasing potentially pathogenic gastro-intestinal microorganisms (ID 1558) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2010;8:1798.

Publication types

Associated data